BIM
NYMX

BlackRock Investment Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

BlackRock Investment Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$12K Hold
4,584
– – ﹤0.01% 3546
2016
Q3 		$15K Hold
4,584
– – ﹤0.01% 3445
2016
Q2 		$15K Buy
+4,584
New +$11.3K ﹤0.01% 3466

Other funds holding NYMX

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock Investment Management's NYMX Position: Q4 2016 in Review

BlackRock Investment Management held its Nymox Pharmaceutical Corp (NYMX) position steady in Q4 2016 at 4,584 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3546.

BlackRock Investment Management first reported a position in NYMX in Q2 2016 and has held it in 3 quarters since. The position peaked at $15K in Q3 2016. 29 funds tracked by Wall St. Rank hold NYMX as of Q4 2016.

  • BlackRock Investment Management held 4,584 shares of Nymox Pharmaceutical Corp worth $12K as of Q4 2016.
  • BlackRock Investment Management left its Nymox Pharmaceutical Corp share count unchanged in Q4 2016.
  • Nymox Pharmaceutical Corp made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3546 holding.
  • BlackRock Investment Management first reported a position in Nymox Pharmaceutical Corp in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Investment Management's Nymox Pharmaceutical Corp position peaked at $15K in Q3 2016.
  • 29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.